Rheumatoid Arthritis: Unravelling the Complexities of a Chronic Autoimmune Disease

Himasri Puppala; Murali Krishna Majji; Amruthamshu Inampudi; Suneetha A; Jahnavi Patibandla

doi:10.38022/ajhp.v5i2.103

Himasri Puppala KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Majji Murali Krishna KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Inampudi Amruthamshu KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
A. Suneetha KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Patibandla Jahnavi KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
jahnavipatibandla@gmail.com

DOI https://doi.org/10.38022/ajhp.v5i2.103

Abstract

Rheumatoid arthritis (RA) is far more than just joint pain-it's a chronic, autoimmune condition that disrupts daily life and challenges healthcare systems worldwide. It begins silently, with the immune system mistakenly turning on the body's own joints, leading to inflammation, swelling, and progressive damage. But RA rarely stops at the joints. It can impact the lungs, heart, eyes, and even mental well-being, making it a truly systemic disease. Its roots lie in a mix of genetic susceptibility-like HLA-DR4-and environmental triggers such as smoking and infections. Fortunately, advances in early diagnosis, especially through the 2010 ACR/EULAR criteria, along with blood markers like anti-CCP and RF, have made it easier to identify the disease before permanent damage occurs.The treatment landscape has transformed dramatically. We now have disease-modifying drugs (DMARDs), biologic therapies, and JAK inhibitors that target inflammation at its source. Complementary strategies-like exercise, physiotherapy, and digital monitoring tools-empower patients to take control of their condition. Yet, despite these advancements, challenges remain: delayed diagnosis, high treatment costs, drug resistance, and unequal access to care continue to hinder progress, especially in low-resource settings. Looking ahead, promising innovations like stem cell therapy, immunomodulatory vaccines, and microbiome-based interventions are paving the way toward a more personalized and hopeful future for people living with RA.

Keywords: Rheumatoid arthritis, autoimmune disease, anti-CCP, DMARDs, biologics, joint inflammation, early diagnosis

Downloads

Download data is not yet available.

References

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
3. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–96.
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
5. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther. 2008;10(2):205.
6. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. Arthritis Rheum. 1987;30(11):1205–13.
7. Kurkó J, Besenyei T, Laki J, et al. Genetics of rheumatoid arthritis—a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):170–9.
8. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659–72.
9. Catrina AI, Deane KD, Scher JU. Gene, environment, and immunity in the development of rheumatoid arthritis. Rheum Dis Clin North Am. 2017;43(3):379–98.
10. Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1–ITC16.
11. Demoruelle MK, Deane KD. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep. 2012;14(5):390–8.
12. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296.
13. van der Woude D, van der Helm-van Mil AH. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174–87.
14. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
15. Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol. 2012;8(10):573–86.
16. van Steenbergen HW, van Nies JA, Huizinga TW. The preclinical phase of rheumatoid arthritis. J Rheumatol. 2013;40(5):513–6.
17. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037–47.
18. Scheel AK, Hermann KG, Ohrndorf S, et al. Prospective 7 year follow up imaging study comparing ultrasound, MRI, and conventional radiography in early RA. Ann Rheum Dis. 2006;65(5):595–600.
19. Conaghan PG. Imaging in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25(4):569–84.
20. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
21. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
22. van Vollenhoven RF. Treat-to-target in rheumatoid arthritis—are we there yet? Nat Rev Rheumatol. 2019;15(3):180–6.
23. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 ACR recommendations for the use of disease-modifying antirheumatic drugs and biologics. Arthritis Care Res. 2012;64(5):625–39.
24. Yates M, Watts RA. Glucocorticoids in rheumatoid arthritis: current status and future prospects. Expert Rev Clin Immunol. 2017;13(3):239–49.
25. Voshaar MJ, Nota I, van de Laar MA. Patient-centred care in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31(5):749–63.
26. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23.
27. Alivernini S, Tolusso B, Ferraccioli G. Precision medicine in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(3):312–7.
28. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update from bench to bedside. Rheumatology. 2014;53(8):1363–75.
29. Widdifield J, Bernatsky S, Thorne JC, et al. Trends in RA incidence and mortality over time: a Canadian population-based study. J Rheumatol. 2019;46(3):315–21.
30. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–8.
31. Mankia K, Emery P. Preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheumatol. 2016;68(4):779–88.
32. van der Heijde D, van der Helm-van Mil AHM. Radiographic progression in RA: moving beyond the joint space. Nat Rev Rheumatol. 2018;14(4):197–206.